Dose-Adjusted EPOCH-R in Aggressive B-Cell Lymphomas: Efficacy, Molecular Prognostic Factors, and Real-World Outcomes from a Multicenter Turkish Cohort-A Turkish Oncology Group (TOG) Study.

Kidi MM, Asoglu H, Soysal M, Koseci T, Kara IO, Sahin B, Paydas S, Aykan MB, Karadurmus N, Barista I, Akin S, Kus F, Akay MO, Kalyon H, Boga C, Ozdogu H, Bayram E

Open source

DOI
10.3390/medicina62061117
Published
2026 Jun 8
Container
Medicina (Kaunas, Lithuania)
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/medicina62061117,
  title = {Dose-Adjusted EPOCH-R in Aggressive B-Cell Lymphomas: Efficacy, Molecular Prognostic Factors, and Real-World Outcomes from a Multicenter Turkish Cohort-A Turkish Oncology Group (TOG) Study.},
  author = {Kidi MM and Asoglu H and Soysal M and Koseci T and Kara IO and Sahin B and Paydas S and Aykan MB and Karadurmus N and Barista I and Akin S and Kus F and Akay MO and Kalyon H and Boga C and Ozdogu H and Bayram E},
  year = {2026},
  journal = {Medicina (Kaunas, Lithuania)},
  doi = {10.3390/medicina62061117},
  url = {https://doi.org/10.3390/medicina62061117}
}

RIS

TY  - JOUR
TI  - Dose-Adjusted EPOCH-R in Aggressive B-Cell Lymphomas: Efficacy, Molecular Prognostic Factors, and Real-World Outcomes from a Multicenter Turkish Cohort-A Turkish Oncology Group (TOG) Study.
AU  - Kidi MM
AU  - Asoglu H
AU  - Soysal M
AU  - Koseci T
AU  - Kara IO
AU  - Sahin B
AU  - Paydas S
AU  - Aykan MB
AU  - Karadurmus N
AU  - Barista I
AU  - Akin S
AU  - Kus F
AU  - Akay MO
AU  - Kalyon H
AU  - Boga C
AU  - Ozdogu H
AU  - Bayram E
PY  - 2026
JO  - Medicina (Kaunas, Lithuania)
DO  - 10.3390/medicina62061117
UR  - https://doi.org/10.3390/medicina62061117
ER  - 

APA

MM, K., H, A., M, S., T, K., IO, K., B, S., S, P., MB, A., N, K., I, B., S, A., F, K., MO, A., H, K., C, B., H, O., & E, B. (2026). Dose-Adjusted EPOCH-R in Aggressive B-Cell Lymphomas: Efficacy, Molecular Prognostic Factors, and Real-World Outcomes from a Multicenter Turkish Cohort-A Turkish Oncology Group (TOG) Study.. Medicina (Kaunas, Lithuania). https://doi.org/10.3390/medicina62061117

Source records